Harrow (HROW) Long-Term Investments (2017 - 2022)
Harrow's (HROW) quarterly Long-Term Investments came in at $2.1 million in Q3 2022, down 62.56% quarter-over-quarter from $5.6 million in Q2 2022.
Harrow (HROW) Long-Term Investments (2017 - 2022) Analysis & Trends
Harrow's Long-Term Investments history runs 6 years deep, the most recent figure standing at $2.1 million for Q3 2022.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $2.1 million in Q3 2022; TTM through Sep 2022 was $2.1 million, a N/A change from a year earlier, with the FY2021 full-year figure at $11.1 million, down 60.88% from the prior year.
- Long-Term Investments fell to $2.1 million in Q3 2022 per HROW's latest filing, from $5.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $28.5 million in Q4 2020 and bottomed at $1.3 million in Q2 2018.
- The 5-year median for Long-Term Investments is $16.7 million (2020), against an average of $15.4 million.
- Across the five-year window, Long-Term Investments soared 2035.14% in 2019 and plunged 91.64% in 2021, its largest moves.
- Year by year, Long-Term Investments stood at $21.4 million in 2018, then rose by 17.65% to $25.2 million in 2019, then advanced by 12.92% to $28.5 million in 2020, then tumbled by 60.88% to $11.1 million in 2021, then slumped by 81.16% to $2.1 million in 2022.
- Per Business Quant, the three latest HROW Long-Term Investments figures stand at $2.1 million (Q3 2022), $5.6 million (Q2 2022), and $8.2 million (Q1 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.32 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 702.35 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 8.25 Mn |
| Dec 31, 2021 | 11.13 Mn |
| Jun 30, 2021 | 1.59 Mn |
| Mar 31, 2021 | 25.62 Mn |
| Dec 31, 2020 | 28.46 Mn |
| Sep 30, 2020 | 27.65 Mn |
| Jun 30, 2020 | 19.08 Mn |
| Mar 31, 2020 | 14.35 Mn |
| Dec 31, 2019 | 25.20 Mn |
| Sep 30, 2019 | 22.12 Mn |
| Jun 30, 2019 | 27.65 Mn |
| Mar 31, 2019 | 28.00 Mn |
| Dec 31, 2018 | 21.42 Mn |
| Sep 30, 2018 | 5.09 Mn |
| Jun 30, 2018 | 1.30 Mn |
| Mar 31, 2018 | 2.44 Mn |
| Dec 31, 2017 | 3.51 Mn |
| Sep 30, 2017 | 4.27 Mn |